Determinants of the quality of a humoral immune response, including the magnitude and isotype of antibody produced, and the extent of affinity maturation, remain poorly defined, limiting efforts of rational vaccine design. Whereas earlier studies had implicated innate immune recognition by Toll-like receptors (TLRs) of B cells in rapid lower affinity antibody responses, our recent studies have shown that innate recognition by TLR9 or TLR7 of B cells strongly enhances the magnitude and the efficacy of the germinal center (GC) response, which generates high quality antibodies. Moreover, this novel function of TLRs has been shown to be required for immune defense against several virus infections in mouse models. In addition, accumulating evidence has indicated that TLR7 and TLR9 are critical components required for the production of anti-nuclear antibodies in mouse models of systemic lupus erythematosus (SLE). Thus, a new pathway whereby TLRs promote high affinity GC antibody responses is likely to be important for immune defense against many viruses and for development of SLE. Recent studies have begun to define the cellular basis by which TLR recognition enhances the magnitude and quality of the IgG response, but the molecular mechanisms underlying this regulation are unknown, which is the topic of this application.
Specific Aim 1 is designed to define the changes in mRNA and microRNA expression in GC B cells experiencing stimulation via their TLR9 compared to GC B cells responding to the same immunization but lacking a functional version of the TLR signaling component MyD88.
Specific Aim 2 will address the hypothesis that key changes in gene expression are concentrated in subsets of GC B cells, namely GC B cells that are receiving selection signals from follicular helper T cells (TFH) and/or have a higher affinity for antigen. This issue will be assessed by microfluidic single cell analysis of gene expression profiles from GC B cells expressing a Myc-GFP reporter (resulting from productive interaction with TFH cells) or from GC B cells of defined affinity for antigen. Understanding the molecular mechanisms of this process will be useful for rational vaccine design and also many provide new targets for development of therapies to treat SLE.

Public Health Relevance

Innate immune recognition of virus nucleic acid by Toll-like receptors expressed by B cells promotes a vigorous and high quality antibody response, but the molecular mechanisms underlying this process are poorly defined. The proposed experiments are designed to define the gene expression changes induced by innate recognition of virus nucleic acid in B cells, which will inform subsequent experiments to identify the molecular mechanisms. Rational vaccine design and therapeutic efforts to interfere with this mechanism in systemic autoimmunity would be aided by progress in understanding these molecular mechanisms,

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI117378-01
Application #
8869351
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ferguson, Stacy E
Project Start
2015-07-01
Project End
2017-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
DeFranco, Anthony L (2017) Innate B cells cleave to the marginal zone. Nat Immunol 18:248-250
Proekt, Irina; Miller, Corey N; Jeanne, Marion et al. (2016) LYN- and AIRE-mediated tolerance checkpoint defects synergize to trigger organ-specific autoimmunity. J Clin Invest 126:3758-3771
DeFranco, Anthony L (2016) Germinal centers and autoimmune disease in humans and mice. Immunol Cell Biol 94:918-924
Lee, Linda M; Ji, Ming; Sinha, Meenal et al. (2016) Determinants of Divergent Adaptive Immune Responses after Airway Sensitization with Ligands of Toll-Like Receptor 5 or Toll-Like Receptor 9. PLoS One 11:e0167693
DeFranco, Anthony L (2016) The germinal center antibody response in health and disease. F1000Res 5: